Quince Therapeutics, Inc. 8-K Filing
Ticker: QNCX · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001662774
| Field | Detail |
|---|---|
| Company | Quince Therapeutics, Inc. (QNCX) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $5.5 m |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Quince Therapeutics, Inc. (ticker: QNCX) to the SEC on Mar 30, 2026.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share QNCX Nasdaq Global Select); $5.5 m (behalf, EUR 4,800,000, or approximately $5.5 million, to the EIB in full settlement of).
How long is this filing?
Quince Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 639 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 639 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2026-03-30 08:35:07
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share QNCX Nasdaq Global Select
- $5.5 m — behalf, EUR 4,800,000, or approximately $5.5 million, to the EIB in full settlement of
Filing Documents
- d57124d8k.htm (8-K) — 26KB
- d57124dex991.htm (EX-99.1) — 8KB
- g57124g0328061252102.jpg (GRAPHIC) — 7KB
- 0001193125-26-130489.txt ( ) — 158KB
- qncx-20260327.xsd (EX-101.SCH) — 3KB
- qncx-20260327_lab.xml (EX-101.LAB) — 18KB
- qncx-20260327_pre.xml (EX-101.PRE) — 11KB
- d57124d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Quince Therapeutics, Inc. By: /s/ Dirk Thye Date: March 30, 2026 Name: Dirk Thye Title: Chief Executive Officer